体外膜氧合启动后PaCO2早期变化与神经系统并发症相关
该多中心、国际、回顾性队列研究利用体外生命支持组织注册数据,纳入2012至2017年间因呼吸衰竭接受ECMO的成人患者11,972例,其中88%为静脉-静脉ECMO。计算启动ECMO后24小时内PaCO2相对变化,主要终点为癫痫发作、缺血性卒中、颅内出血或脑死亡组成的神经系统并发症。PaCO2中位相对变化为-31%(IQR -46%至-12%),神经系统并发症总发生率6.9%。PaCO2相对下降>50%者神经系统并发症发生率为9.8%,高于下降较小者的6.4%(P<0.001);校正既往已知危险因素后,大幅相对下降仍与神经系统并发症独立相关(OR 1.7,95%CI 1.3-2.3,P<0.001)。
要点
- 呼吸衰竭成人启动ECMO后24小时内PaCO2相对下降>50%者,神经系统并发症发生率9.8%,高于下降较小者的6.4%(P<0.001)。
- 校正既往已知危险因素后,PaCO2大幅相对下降与神经系统并发症独立相关(OR 1.7,95%CI 1.3-2.3,P<0.001)。
- 总体神经系统并发症发生率6.9%,其中癫痫1.1%、缺血性卒中1.9%、颅内出血3.5%、脑死亡1.6%。
- PaCO2相对变化中位数为-31%(IQR -46%至-12%),计算方式为(ECMO后24小时PaCO2-ECMO前PaCO2)/ECMO前PaCO2。
- 该研究为多中心国际回顾性队列,88%患者接受静脉-静脉ECMO。
适用人群与场景
- 2012至2017年间因呼吸衰竭接受ECMO(任何模式)的成人患者,数据来自体外生命支持组织注册库。
诊断标准与关键阈值
- PaCO2相对变化=(ECMO后24小时PaCO2-ECMO前PaCO2)/ECMO前PaCO2;大幅相对下降定义为>50%。
研究设计与关键结果
- 多中心、国际、回顾性队列研究,纳入11,972例因呼吸衰竭接受ECMO的成人患者,88%为静脉-静脉ECMO。
- 主要终点为神经系统并发症(癫痫发作、缺血性卒中、颅内出血或脑死亡),总发生率6.9%;癫痫1.1%、缺血性卒中1.9%、颅内出血3.5%、脑死亡1.6%。
- PaCO2中位相对变化为-31%(IQR -46%至-12%)。
- PaCO2相对下降>50%者神经系统并发症发生率9.8%,下降较小者为6.4%(P<0.001)。
- 校正既往已知危险因素后,PaCO2大幅相对下降与神经系统并发症独立相关(OR 1.7,95%CI 1.3-2.3,P<0.001)。
证据类型、等级与局限
- 证据类型:多中心、国际、回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,呼吸衰竭患者启动ECMO后24小时内PaCO2大幅相对下降(>50%)与神经系统并发症独立相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Large decreases in PaCO2 that occur when initiating extracorporeal membrane oxygenation (ECMO) in patients with respiratory failure may cause cerebral vasoconstriction and compromise brain tissue perfusion.Objectives: To determine if the magnitude of PaCO2 correction upon ECMO initiation is associated with an increased incidence of neurological complications in patients with respiratory failure.Methods: We conducted a multicenter, international, retrospective cohort study using the Extracorporeal Life Support Organization Registry, including adults with respiratory failure receiving ECMO via any mode between 2012 and 2017. The relative change in PaCO2 in the first 24 hours was calculated as (24-h post-ECMO PaCO2 - pre-ECMO PaCO2)/pre-ECMO PaCO2. The primary outcome was the occurrence of neurological complications, defined as seizures, ischemic stroke, intracranial hemorrhage, or brain death.Measurements and Main Results: We included 11,972 patients, 88% of whom were supported with venovenous ECMO. The median relative change in PaCO2 was -31% (interquartile range, -46% to -12%). Neurological complications were uncommon overall (6.9%), with a low incidence of seizures (1.1%), ischemic stroke (1.9%), intracranial hemorrhage (3.5%), and brain death (1.6%). Patients with a large relative decrease in PaCO2 (>50%) had an increased incidence of neurological complications compared with those with a smaller decrease (9.8% vs. 6.4%; P < 0.001). A large relative decrease in PaCO2 was independently associated with neurological complications after controlling for previously described risk factors (odds ratio, 1.7; 95% confidence interval, 1.3 to 2.3; P < 0.001).Conclusions: In patients receiving ECMO for respiratory failure, a large relative decrease in PaCO2 in the first 24 hours after ECMO initiation is independently associated with an increased incidence of neurological complications.
参考来源
- Cavayas YA, Munshi L, Del Sorbo L, et al. The Early Change in PaCO2 after Extracorporeal Membrane Oxygenation Initiation Is Associated with Neurological Complications. Am J Respir Crit Care Med. 2020. PMID: 32251606. doi:10.1164/rccm.202001-0023OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。